Use antibodies to deliver protein-destroying drugs into the right cells
Drugs that destroy proteins can hit healthy cells too. Attaching them to an antibody that only docks onto tumour cells would keep them where they are needed.
Degrader-antibody conjugates replace cytotoxic payloads with a targeted protein degrader, so the payload is only released inside antigen-positive cells. Early programmes target BRD4 and other essential proteins that are too toxic to degrade systemically. This is a route to attack undruggable but essential nuclear proteins that would otherwise be intolerable.
- The undruggable drivers · The proteins that drive most cancers, such as MYC, mutant p53 and most RAS variants, still have no good drug.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
Pages like this
not linked directly; found by shared links- IdeaFind E3 ligases that only tumours have, and build degraders around them
Shares Nurix Therapeutics, Kymera Therapeutics, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaScreen glue-like compounds against every cancer cell line and publish it
Shares Nurix Therapeutics, Kymera Therapeutics, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaDesign protein degraders small enough to get into the brain
Shares Nurix Therapeutics, Kymera Therapeutics, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- TechnologyMolecular glue discovery platforms
Shares Degrader-antibody conjugate (DAC), Nurix Therapeutics, Kymera Therapeutics, PROTACs & molecular glues (targeted protein degradation).
- IdeaMolecular glues that break the MYC-MAX partnership
Shares Kymera Therapeutics, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaTumour-on-a-chip with blood flow to test whether big drugs actually get in
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
- TermMMAF
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
- TermDM1
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).